Tools for the Individualized Therapy of Teicoplanin for Neonates and Children.

ABSTRACT: The aim of this study was to develop a population pharmacokinetic (PK) model for teicoplanin across childhood age ranges to be used as Bayesian prior information in the software constructed for individualized therapy. We developed a nonparametric population model fitted to PK data from neonates, infants, and older children. We then implemented this model in the BestDose multiple-model Bayesian adaptive control algorithm to show its clinical utility. It was used to predict the dosages required to achieve optimal teicoplanin predose targets (15 mg/liter) from day 3 of therapy. We performed individual simulations for an infant and a child from the original population, who provided early first dosing interval concentration-time data. An allometric model that used weight as a measure of size an

SUBMITTER: Ramos-Martin V 

PROVIDER: S-EPMC5610524 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature